期刊文献+

非注射途径胰岛素制剂的研究进展 被引量:8

Progress in non-invasive routes for insulin preparations
下载PDF
导出
摘要 非注射途径胰岛素制剂主要包括:肺吸入剂、口服制剂、黏膜给药制剂以及经皮给药系统。本文从以上几个类型介绍了近年来非注射途径胰岛素制剂的研究动态及较有前景的给药途径,为糖尿病治疗药物的研究与开发提供参考。 Acceptable alternative mutes of insulin administration, such as pulmonary inhaled, oral, buccal, nasal and dermal approaches and delivery systems have been investigated over the last decades. Research advances and promising routes for noninjectable insulin delivery were reviewed in this paper, aiming to provide some references for research and development of drags for diabetic disease.
作者 蔡乐 朱珠
出处 《中国药科大学学报》 CAS CSCD 北大核心 2007年第2期105-107,共3页 Journal of China Pharmaceutical University
关键词 胰岛素 非注射途径 肺吸入剂 insulin non-invasive routes pulmonary inhaled preparations
  • 相关文献

参考文献14

  • 1Alberti KG.Treating type 2 diabetes-today's targets,tomorrow's goals[J].Diabetes Obes Metab,2001,3(1):S3-10.
  • 2王强,刘新月,李乃适.临床常用胰岛素制剂的分类及特点[J].临床药物治疗杂志,2005,3(6):47-52. 被引量:21
  • 3蔡乐,朱珠,王强,刘新月.胰岛素类似物与新型降糖激素类药物[J].中国新药杂志,2007,16(6):432-437. 被引量:26
  • 4Shaikh IM,Jadhav KR,Ganga S,et al.Advanced approaches in insulin delivery[J].Curr Pharm Biotechnol,2005,6(5):387-395.
  • 5Cefalu WT.Evolving strategies for insulin delivery and therapy[J].Drugs,2004,64(11):1149-1161.
  • 6Morton-Eggleston E,Barrett EJ.Inhaled insulin[J].BMJ,2006,332(7 549):1043-1044.
  • 7Pfizer Inc.Exubera(drug insert)[EB/OL].NY,NY:Pfizer Inc,2006[2006-8-1].http://www.pfizer.com/pfizer/download/uspiexubera.pdf.
  • 8Brain JD.Unlocking the opportunity of tight glycaemic control.Inhaled insulin:safety[J].Diabetes Obes Metab,2005,7(Suppl 1):14-18.
  • 9Gonzalez C,Kanevsky D,De Marco R,et al.Non-invasive routes for insulin administration:current state and perspectives[J].Expert Opin Drug Deliv,2006,3(6):763-770.
  • 10王祥香,孙子林.糖尿病药物治疗新进展——来自2005年欧洲糖尿病年会的最新信息[J].中国药科大学学报,2006,37(2):105-110. 被引量:9

二级参考文献56

  • 1黄胜炎.胰岛素新制剂研究进展[J].上海医药,2005,26(4):166-170. 被引量:11
  • 2王强,刘新月,李乃适.临床常用胰岛素制剂的分类及特点[J].临床药物治疗杂志,2005,3(6):47-52. 被引量:21
  • 3李乃适,伍学焱,覃舒文,李梅,顾锋,潘慧,夏维波,王鸥,郑欣,周洁,向红丁.胰岛素制剂过敏的临床特征与处理——附7例分析[J].中华糖尿病杂志(1006-6187),2005,13(5):360-362. 被引量:31
  • 4[1]Matindale pharmacopoeia,33 edition,324
  • 5[2]金有豫主译.古德曼吉尔曼治疗学的药理学基础.第10版.北京:人民卫生出版社,2004:1316~1318
  • 6[4]Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long - acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.Diabetes,2000,49(12): 2142 ~2148
  • 7Dey D,Anumula M,Pandey B,et al.Mechanism of action studies with novel thiazolidinedione BLX-1002 with no PPARγ affinity[J].Diabetologia,2005,48(S1):A44.
  • 8Fagerberg B,Edwards S,Halmos T,et al.Improvement in postprandial lipid handing and glucose tolerance with tesaglitazar in insulin-resistant,nondiabetic patients[J].Diabetologia,2005,48(S1):A274.
  • 9Frederich R,Mohideen P,DePril V,et al.Attainment of HbA1c goals in type 2 diabetes patients treated with muraglitazar,a novel dual(α/γ)PPAR activator:experience from 3 large placebo-controlled trials[J].Diabetologia,2005,48(S1):A16.
  • 10Mohideen P,Bancken F,Rubin CJ,et al.Glycemic efficacy and tolerability of muraglitazar,a novel dual(α/γ)PPAR activator,Plus metformin in patients with type 2 diabetes and inadequate glucemic control[J].Diabetologia,2005,48(S1):274-275.

共引文献51

同被引文献146

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部